Gyre Therapeutics Q3 revenue misses; lowers FY revenue guidance

Gyre Therapeutics

07/11/2025 11:11

Overview

Gyre Q3 revenue up 20% yr/yr, but missed analyst expectations

Net income for Q3 doubled to $5.9 mln, reflecting cost control

Full-year revenue guidance revised down due to Etorel rollout delays

Outlook

Gyre revises full-year revenue guidance to $115-118 mln due to Etorel® rollout delays

Company expects continued ETUARY® sales growth to offset challenges with Etorel® and Contiva®

Gyre plans to initiate Phase 2/3 trial for pirfenidone in Q4 2025

Result Drivers

For the three months ended September 30, 2025, research and development expense was $2.4 million, compared to $2.8 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$30.56 mln
$34 mln (2 Analysts)
Q3 Net Income
$5.94 mln
Q3 Operating Profit
$6.93 mln
Q3 Pretax Profit
$7.63 mln


Press Release: ID:nGNX3dK9KJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)